Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

Sun launches Exelon generic in US


Sun Pharmaceutical Industries has said it has launched a generic version of Exelon capsules, used for the treatment of dementia, in the US market. The generic Rivastigmine capsules, which are equivalent to Novartis' Exelon, have been launched in strengths of 1.5 mg, 3 mg, 4.5 mg and 6 mg, Sun Pharma said in a statement. These strengths of Exelon have annual sales of nearly $130 million in the US, it added. The company, being one of the first to file an Abbreviated New Drug Application for the generic Exelon, will share a 180-day marketing exclusivity, the statement added. The drug is for treating mild to moderate dementia of the Alzheimer's type and for mild to moderate dementia associated with the Parkinson's disease. Shares of Sun Pharma closed down 0.02 per cent on the BSE at Rs 1754.75 on Friday. '